NET ASSET VALUE – 30 September 2024

MARKN.

On the 30 September 2024 Flerie AB's Net Asset Value (NAV) was SEK 4,262 million and NAV per share was SEK 54.59.



Allocation of NAV
Share of portfolio companyFair value (MSEK)Part of NAV per share (SEK)Share of NAV
Product Development    
Prokarium42%4756.0911.1%
Xspray Pharma18%2943.776.9%
Empros Pharma79%2042.624.8%
KAHR Medical31%1912.444.5%
Atrogi37%1762.254.1%
Xintela56%1652.113.9%
Lipum57%1642.103.8%
Microbiotica11%1351.733.2%
Geneos Therapeutics12%971.242.3%
Mendus24%961.232.3%
EpiEndo Pharmaceuticals9%560.721.3%
Toleranzia58%560.711.3%
Synerkine Pharma43%520.671.2%
AnaCardio19%520.661.2%
Egetis Therapeutics2%370.470.9%
Buzzard Pharmaceuticals14%290.370.7%
Sixera Pharma23%260.330.6%
Alder Therapeutics21%170.220.4%
Vitara Biomedical5%130.170.3%
Amarna Therapeutics58%110.150.3%
Strike Pharma16%90.110.2%
Total 2,35430.1655.2%





Commercial Growth   
NorthX Biologics92%1892.424.4%
Symcel31%1692.164.0%
Chromafora31%730.931.7%
Provell Pharmaceuticals72%690.881.6%
A3P Biomedical8%420.541.0%
Nanologica39%390.500.9%
Frontier Biosolutions2%190.240.4%
Bohus Biotech45%170.210.4%
Total 6167.8914.5%





Limited Partnerships, total 921.182.2%
     
Assets related to Portfolio companies 2893.706.8%
Other assets and liabilities 91011.6621.4%
     
NAV 4,26254.59100.0%
  

 

    

* indirect shares in Provell Pharmaceuticals

Datum 2024-10-04, kl 08:00
Källa MFN
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet